GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC acquires Selectis Health, Inc. for USD 15,700,000 (2026)

Deal facts

Buyer: GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC
Target: Selectis Health, Inc.
Deal value: USD 15,700,000
Announced: 7 May 2026
Status: Completed
Sector: Healthcare
Country: United States
Consideration: cash

Sources

SEC_EDGAR_8K

What we know

Weekly digest

Join Exit Mode Insider

Ten deal briefs a week, founder commentary, and the patterns worth paying attention to.

Join Exit Mode Insider, £12/mo

Deal timeline

1 update

1 May 2026CompletedClosed
GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC completes acquisition of Selectis Health, Inc.
Item 2.01 Completion of Acquisition or Disposition of Assets. On May 1, 2026, certain wholly-owned subsidiaries (collectively the “Sellers”) of Selectis Health, Inc. (the “Company”) GLOBAL ABBEVILLE PROPERTY, LLC and DODGE NH, LLC, each a Georgia limited liability company, consummated a definitive Purchase and Sale Agreement (“PSA”) with GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC, both limi
Source

OpinionExit Mode editorial

We see a clear signal in the completion of the asset sale of Selectis Health, Inc. by two newly formed US entities, GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC. The deal, announced on 7 May 2026 and valued at 15.7 million USD, is a straightforward cash transaction within the US healthcare sector. This structure is not merely a change of ownership but a deliberate operational reset. By choosing an asset sale over a share purchase, the buyers have likely sought to isolate specific liabilities while retaining the core clinical or administrative assets they value. For the SME founder in the UK watching this transatlantic move, the mechanics matter as much as the headline price.

The use of a pure cash consideration in an asset deal often points to a desire for speed and certainty, bypassing the complexities of share exchange or deferred payment structures. In the healthcare sector, this approach frequently triggers specific change-of-control covenants with key payers or regulatory bodies that require immediate notification or approval. While the deal is marked as completed, the underlying regulatory context in the US means that competition authorities or health service regulators would have scrutinised the transfer of patient data and service contracts. The buyers have taken on the burden of re-establishing these relationships, a risk that the seller effectively shed by selling assets rather than the corporate shell.

Our view is that this transaction highlights a growing trend where private equity or specialist operators prefer to carve out specific business units to avoid inheriting legacy liabilities. The clean break offered by an asset sale can be attractive to founders who have built a valuable operation but face a complex corporate history. However, this route demands rigorous due diligence on the assets being transferred to ensure no hidden obligations follow the buyer. The simplicity of the cash deal should not mask the operational friction that comes with transferring contracts and staff under a new legal entity.

You should review your own customer and supplier contracts this week to identify any change-of-control clauses that could be triggered by a future asset sale. Map out which assets are essential to your valuation and which liabilities you would prefer to leave behind, so you can structure a potential exit that mirrors the certainty seen in this US healthcare deal.

Editorial opinion. Not financial or legal advice.

Explore

Browse adjacent archives

Jump from this deal into the sector, buyer, deal type, and year views that carry the strongest contextual signal.

More Healthcare deals More 2026 deals More asset sale deals More from GA SNF ABBEVILLE GA LLC and GA SNF EASTMAN GA LLC All M&A deals

Similar deals

Other Healthcare M&A activity tracked by Exit Mode.

15 April 2026CompletedHealthcare

MeiraGTx Holdings plc to acquire Janssen Pharmaceuticals, Inc.

MeiraGTx Holdings plc and Janssen Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: MeiraGTx Holdings plc
Target: Janssen Pharmaceuticals, Inc.
Deal value: USD 25,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

7 April 2026Firm intentionHealthcare

Supernus Pharmaceuticals, Inc. to acquire Navitor Pharmaceuticals, Inc.

Supernus Pharmaceuticals, Inc. and Navitor Pharmaceuticals, Inc. entered the Exit Mode archive.

Buyer: Supernus Pharmaceuticals, Inc.
Target: Navitor Pharmaceuticals, Inc.
Deal value: USD 350,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

30 March 2026Firm intentionHealthcare

SCYNEXIS, Inc. to acquire Poxel SA

SCYNEXIS, Inc. and Poxel SA entered the Exit Mode archive.

Buyer: SCYNEXIS, Inc.
Target: Poxel SA
Deal value: USD 8,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals France deals

25 March 2026CompletedHealthcare

Vireo Health of Rocky Mountain, LLC to acquire Medicine Man Technologies, Inc. d/b/a Schwazze

Vireo Health of Rocky Mountain, LLC and Medicine Man Technologies, Inc. d/b/a Schwazze entered the Exit Mode archive.

Buyer: Vireo Health of Rocky Mountain, LLC
Target: Medicine Man Technologies, Inc. d/b/a Schwazze
Deal value: USD 111,000,000
Deal type: asset sale

Read deal Healthcare deals asset sale deals United States deals

2 January 2026CompletedHealthcare

Sunstring Ltd to acquire A.M.S 2000 Trading Impex SRL

Sunstring Ltd has agreed to acquire the assets of A.M.S 2000 Trading Impex SRL, a diagnostics distributor based in Israel, in a transaction structured as an asset sale.…

Buyer: Sunstring Ltd
Target: A.M.S 2000 Trading Impex SRL
Deal value: Not disclosed
Deal type: asset sale

Read deal Healthcare deals asset sale deals Israel deals

Buyer history